1996
Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation
Horwitz R, Singer B, Makuch R, Viscoli C. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Journal Of Clinical Epidemiology 1996, 49: 395-400. PMID: 8621989, DOI: 10.1016/0895-4356(95)00058-5.Peer-Reviewed Original ResearchConceptsClinical inquiryBeta-Blocker Heart Attack TrialCoronary artery surgeryHeart Attack TrialSubgroup of patientsArtery surgeryAspirin useCoronary surgeryMulticenter RCTClinical featuresAttack TrialClinical centersClinical conditionsTreatment groupsPatientsBenefit of propranololClinical decisionTrial resultsHeterogeneous groupPropranololRCTsSurgeryTreatmentTrialsOverall benefit
1985
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers